{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:21:17Z","timestamp":1791084077880,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jhep.2017.03.027","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T08:18:47Z","timestamp":1491553127000},"page":"246-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy"],"prefix":"10.1016","volume":"67","author":[{"given":"Elham","family":"Shirvani-Dastgerdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Y.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Celi\u00e0-Terrassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eray","family":"Yagmur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Rodr\u00edguez-Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ploss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.03.027_b0005","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.03.027_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.027_b0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/liv.12069","article-title":"Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance","volume":"33","author":"Zoulim","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.027_b0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.027_b0025","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.027_b0030","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2893.2010.01378.x","article-title":"Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains","volume":"18","author":"Amini-Bavil-Olyaee","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.03.027_b0035","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2017.03.027_b0040","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir","volume":"10","author":"Sheldon","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2017.03.027_b0045","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.22790","article-title":"The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains","volume":"49","author":"Amini-Bavil-Olyaee","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.027_b0050","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.027_b0055","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1086\/597808","article-title":"Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients","volume":"199","author":"Margeridon-Thermet","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2017.03.027_b0060","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jhep.2009.04.022","article-title":"Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome","volume":"51","author":"Amini-Bavil-Olyaee","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.027_b0065","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.cmi.2015.09.020","article-title":"Hepatitis delta virus facilitates the selection of hepatitis B virus mutants in vivo and functionally impacts on their replicative capacity in vitro","volume":"22","author":"Shirvani-Dastgerdi","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2017.03.027_b0070","doi-asserted-by":"crossref","first-page":"8524","DOI":"10.1128\/JVI.78.16.8524-8535.2004","article-title":"Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants","volume":"78","author":"Tacke","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2017.03.027_b0075","article-title":"Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction","author":"Yang","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhep.2017.03.027_b0080","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1128\/JVI.01796-09","article-title":"Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains","volume":"84","author":"Amini-Bavil-Olyaee","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2017.03.027_b0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jinf.2013.05.008","article-title":"Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen","volume":"67","author":"Cento","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.jhep.2017.03.027_b0090","article-title":"Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.03.027_b0095","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/hep.25928","article-title":"Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates","volume":"56","author":"van Breugel","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.027_b0100","article-title":"Characterization of novel hepatitis B virus PreS\/S-gene mutations in a patient with occult hepatitis B virus infection","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.03.027_b0105","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2016.09.005","article-title":"Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA","volume":"66","author":"Xiang","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.027_b0110","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/JVI.00243-16","article-title":"Single-molecule sequencing reveals complex genome variation of hepatitis B virus during 15 years of chronic infection following liver transplantation","volume":"90","author":"Betz-Stablein","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2017.03.027_b0115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.22295","article-title":"The antiviral drug selected hepatitis B virus rtA181T\/sW172\u2217 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound","volume":"48","author":"Warner","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.027_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.07.009","article-title":"Hepatocarcinogenesis associated with hepatitis B, delta and C viruses","volume":"20","author":"Shirvani-Dastgerdi","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhep.2017.03.027_b0125","article-title":"Identification of transforming hepatitis B virus S gene nonsense mutations derived from freely replicative viruses in hepatocellular carcinoma","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.03.027_b0130","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.027_b0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.diagmicrobio.2014.01.005","article-title":"Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method","volume":"79","author":"Ciftci","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jhep.2017.03.027_b0140","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","article-title":"Entecavir resistance is rare in nucleoside naive patients with hepatitis B","volume":"44","author":"Colonno","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.027_b0145","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1128\/AAC.00833-06","article-title":"Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present","volume":"51","author":"Tenney","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.027_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106324","article-title":"Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus","volume":"9","author":"van Hemert","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.03.027_b0155","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1128\/AAC.01499-06","article-title":"The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro","volume":"51","author":"Warner","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.027_b0160","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3748\/wjg.v20.i2.425","article-title":"Core promoter: a critical region where the hepatitis B virus makes decisions","volume":"20","author":"Quarleri","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.027_b0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3748\/wjg.v13.i1.22","article-title":"Viral and cellular determinants involved in hepadnaviral entry","volume":"13","author":"Glebe","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.027_b0170","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479\u2013480","author":"Seeger","year":"2015","journal-title":"Virology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817301988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817301988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T04:47:09Z","timestamp":1658897229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817301988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0168827817301988"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.03.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}